Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aclidinium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 20/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 18/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 17/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | TACR1 | P25103 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aclidinium SCHEMBL72693 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Aclidinium SCHEMBL29351588 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Aclidinium SCHEMBL2075481 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Aclidinium SCHEMBL72141 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Aclidinium SCHEMBL72140 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL73282 | 0.97 | CHRM3 (0.96) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL73281 | 0.97 | CHRM3 (0.96) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL71791 | 0.95 | CHRM3 (0.91) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL73023 | 0.94 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL73022 | 0.94 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10588895-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2020-03-17 | — | — | US | claimed |
| US-20190183867-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL SA (ES) | 2019-06-20 | — | — | US | claimed |
| US-10087177-B2 | Process for the preparation of aclidinium bromide | HOVIONE SCIENTIA LIMITED (IE) | 2018-10-02 | — | — | US | claimed |
| US-20180200234-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS | ALMIRALL, S.A. (ES) | 2018-07-19 | — | — | US | claimed |
| US-20180105517-A1 | Process for the Preparation of Aclidinium Bromide | HOVIONE SCIENTIA LIMITED (IE) | 2018-04-19 | — | — | US | claimed |
| EP-3277679-A1 | PROCESS FOR THE PREPARATION OF ACLIDINIUM BROMIDE | Hovione Scientia Limited (IE) | 2018-02-07 | — | — | EP | claimed |
| US-20170049756-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | GRAS ESCARDO JORDI (ES) | 2017-02-23 | — | — | US | claimed |
| WO-2016156836-A1 | PROCESS FOR THE PREPARATION OF ACLIDINIUM BROMIDE | HOVIONE SCIENTIA LIMITED (IE) | 2016-10-06 | — | — | WO | claimed |
| US-20160038470-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS | GRAS ESCARDO JORDI (ES) | 2016-02-11 | — | — | US | claimed |
| US-20150306079-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | GRAS ESCARDO JORDI (ES) | 2015-10-29 | — | — | US | claimed |
| US-20060205702-A1 | Combinations comprising antimuscarinic agents and corticosteroids | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-09-14 | — | — | US | claimed |
| US-20060189651-A1 | Combinations comprising antimuscarinic agents and beta-adrenergic agonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-08-24 | — | — | US | claimed |
| US-7078412-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL PRODESFARMA AG (CH) | 2006-07-18 | — | — | US | claimed |
| US-20060154934-A1 | Combinations comprising antimuscarinic agents and PDE4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-07-13 | — | — | US | claimed |
| US-20050288266-A1 | Combinations comprising antimuscarinic agents and corticosteroids | GRAS ESCARDO JORDI | 2005-12-29 | — | — | US | claimed |
| WO-2005115467-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS | ALMIRALL PRODESFARMA S.A. (ES) | 2005-12-08 | — | — | WO | claimed |
| WO-2005115466-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS | ALMIRALL PRODESFARMA S.A. (ES) | 2005-12-08 | — | — | WO | claimed |
| WO-2005115462-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | ALMIRALL PRODESFARMA S.A. (ES) | 2005-12-08 | — | — | WO | claimed |
| US-20050267135-A1 | Combinations comprising antimuscarinic agents and PDE4 inhibitors | ESCARDO JORDI G | 2005-12-01 | — | — | US | claimed |
| US-20050209272-A1 | 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane in salt form, particularly bromide or trifluoroacetate, for treatment of respiratory disorders, alone or in combination with other bronchodilatory compounds | ALMIRALL PRODESFARMA, S.A. (ES) | 2005-09-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189651-A1 | Combinations comprising antimuscarinic agents and beta-adrenergic agonists | ADRB2, ADRB3, CHRM3 | CHRM3 3/4885CHRM2 4/4885CHRM1 11/4885 |
| US-10087177-B2 | Process for the preparation of aclidinium bromide | ACMSD, CHRND, ADRA2B | CHRM3 119/4885CHRM2 34/4885CHRM1 230/4885 |
| US-20170049756-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | CHRM3, PDE4A, CHRM4 | CHRM3 1/4885CHRM2 4/4885CHRM1 8/4885 |
| US-20180200234-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS | ADRB2, ADRB3, CHRM3 | CHRM3 3/4885CHRM2 4/4885CHRM1 11/4885 |
| US-20050267135-A1 | Combinations comprising antimuscarinic agents and PDE4 inhibitors | CHRM3, PDE4A, CHRM4 | CHRM3 1/4885CHRM2 4/4885CHRM1 8/4885 |
| US-20150306079-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | CHRM3, PDE4A, CHRM4 | CHRM3 1/4885CHRM2 4/4885CHRM1 8/4885 |
| US-20050209272-A1 | 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane in salt form, particularly bromide or trifluoroacetate, for treatment of respiratory disorders, alone or in combination with other bronchodilatory compounds | NR3C2, NR3C1, NR4A3 | CHRM3 9/4885CHRM2 30/4885CHRM1 64/4885 |
| US-20190183867-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRNB1, ARRB1 | CHRM3 1/4885CHRM2 4/4885CHRM1 5/4885 |
| US-20060154934-A1 | Combinations comprising antimuscarinic agents and PDE4 inhibitors | CHRM3, PDE4A, CHRM4 | CHRM3 1/4885CHRM2 4/4885CHRM1 8/4885 |
| US-20060205702-A1 | Combinations comprising antimuscarinic agents and corticosteroids | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM1 3/4885 |
| US-20160038470-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM1 3/4885 |
| US-10588895-B2 | Quinuclidine derivatives and medicinal compositions containing the same | CHRM3, QDPR, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 8/4885 |
| US-20050288266-A1 | Combinations comprising antimuscarinic agents and corticosteroids | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM1 3/4885 |
| US-20180105517-A1 | Process for the Preparation of Aclidinium Bromide | ACMSD, CHRND, ADRA2B | CHRM3 119/4885CHRM2 34/4885CHRM1 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.